This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Lely, A. J. Articles by Lamberts, S. W. Search for Related Content PubMed PubMed Citation Articles by van der Lely, A. J. Articles by Lamberts, S. W.

Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

Department of Internal Medicine (A.J.v.d.L., A.F.M., J.A.J., S.W.L.), Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands; and Sensus Drug Development Corporation (R.J.D., K.A.Z., J.A.S.), Austin, Texas 78701

Address correspondence and requests for reprints to: A. J. van der Lely, M.D., Department of Internal Medicine, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands. E-mail: vanderlely{at}inw3.azr.nl

We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.

This article has been cited by other articles:

				S. J. C. M. M. Neggers, M. O. van Aken, J. A. M. J. L. Janssen, R. A. Feelders, W. W. de Herder, and A.-J. van der Lely Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4598 - 4601. [Abstract] [Full Text] [PDF]

				A N Paisley, K Hayden, A Ellis, J Anderson, G Wieringa, and P J Trainer Pegvisomant interference in GH assays results in underestimation of GH levels Eur. J. Endocrinol., March 1, 2007; 156(3): 315 - 319. [Abstract] [Full Text] [PDF]

				J. O. L. Jorgensen, U. Feldt-Rasmussen, J. Frystyk, J.-W. Chen, L. O. Kristensen, C. Hagen, and H. Orskov Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5627 - 5631. [Abstract] [Full Text] [PDF]

				G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]

				A. F. Muller, J. J. Kopchick, A. Flyvbjerg, and A. J. van der Lely Growth Hormone Receptor Antagonists J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1503 - 1511. [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767. [Abstract] [Full Text] [PDF]

				Z Merza Modern treatment of acromegaly Postgrad. Med. J., April 1, 2003; 79(930): 189 - 194. [Abstract] [Full Text] [PDF]

				P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]